These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18978345)

  • 1. A phase I study of periocular topotecan in children with intraocular retinoblastoma.
    Chantada GL; Fandino AC; Carcaboso AM; Lagomarsino E; de Davila MT; Guitter MR; Rose AB; Manzitti J; Bramuglia GF; Abramson DH
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1492-6. PubMed ID: 18978345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
    Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
    Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy.
    Carcaboso AM; Bramuglia GF; Chantada GL; Fandiño AC; Chiappetta DA; de Davila MT; Rubio MC; Abramson DH
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3761-7. PubMed ID: 17652749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma.
    Schaiquevich P; Ceciliano A; Millan N; Taich P; Villasante F; Fandino AC; Dominguez J; Chantada GL
    Pediatr Blood Cancer; 2013 May; 60(5):766-70. PubMed ID: 23024125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
    Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
    J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
    Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
    Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
    Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery).
    Abramson DH; Dunkel IJ; Brodie SE; Marr B; Gobin YP
    Ophthalmology; 2010 Aug; 117(8):1623-9. PubMed ID: 20381868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Periocular topotecan for intraocular retinoblastoma.
    Mallipatna AC; Dimaras H; Chan HS; Héon E; Gallie BL
    Arch Ophthalmol; 2011 Jun; 129(6):738-45. PubMed ID: 21670340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment.
    Buitrago E; Höcht C; Chantada G; Fandiño A; Navo E; Abramson DH; Schaiquevich P; Bramuglia GF
    Exp Eye Res; 2010 Jul; 91(1):9-14. PubMed ID: 20307538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma.
    Taich P; Ceciliano A; Buitrago E; Sampor C; Fandino A; Villasante F; Lucena E; Romero L; Chantada GL; Schaiquevich P
    Ophthalmology; 2014 Apr; 121(4):889-97. PubMed ID: 24359624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
    Lotz JP; Pautier P; Selle F; Viens P; Fabbro M; Lokiec F; Viret F; Gligorov J; Gosse B; Provent S; Ribrag V; Micléa JM; Dosquet C; Goetschel A; Cailliot C; Lefèvre G; Genève J; Lhommé C;
    Bone Marrow Transplant; 2006 Apr; 37(7):669-75. PubMed ID: 16501591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.
    Abramson DH; Dunkel IJ; Brodie SE; Kim JW; Gobin YP
    Ophthalmology; 2008 Aug; 115(8):1398-404, 1404.e1. PubMed ID: 18342944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
    Laurie NA; Gray JK; Zhang J; Leggas M; Relling M; Egorin M; Stewart C; Dyer MA
    Clin Cancer Res; 2005 Oct; 11(20):7569-78. PubMed ID: 16243833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
    Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
    J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of oral topotecan in hematological malignancies.
    Beran M; O'Brien S; Thomas DA; Tran HT; Cortes-Franco JE; Giles F; Estey E; Kantarjian HM
    Clin Cancer Res; 2003 Sep; 9(11):4084-91. PubMed ID: 14519630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
    Santana VM; Zamboni WC; Kirstein MN; Tan M; Liu T; Gajjar A; Houghton PJ; Stewart CF
    Clin Cancer Res; 2003 Feb; 9(2):633-40. PubMed ID: 12576429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.
    Delord JP; Léger F; Canal P; Poublanc M; Bugat R; Chatelut E
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):189-94. PubMed ID: 16328415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.